Vera Therapeutics (VERA) Net Cash Flow (2020 - 2026)

Vera Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$240.4 million for Q1 2026.

• Quarterly Net Cash Flow fell 540.04% year-over-year to -$240.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.3 million (up 522.84% YoY) and the FY2025 annual result came in at $262.1 million, up 458.03% from the prior year.
• Net Cash Flow was -$240.4 million for Q1 2026 at Vera Therapeutics, down from $297.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $297.0 million in Q4 2025 and bottomed at -$240.4 million in Q1 2026.
• A 5-year average of $2.0 million and a median of $2.2 million in 2024 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow soared 867.22% — and 2026, when it plunged 540.04%.
• Vera Therapeutics' Net Cash Flow stood at $13.0 million in 2022, then surged by 40.48% to $18.2 million in 2023, then jumped by 258.5% to $65.4 million in 2024, then jumped by 354.12% to $297.0 million in 2025, then slumped by 180.95% to -$240.4 million in 2026.
• Business Quant data shows VERA's Net Cash Flow at -$240.4 million in Q1 2026, $297.0 million in Q4 2025, and $8.7 million in Q3 2025.